



**Barcelona
Supercomputing
Center**
Centro Nacional de Supercomputación

Technical and scientific challenges in biomedicine: an European perspective.



Esade Forum-Pedralbes Campus

Alfonso Valencia. Ph.D.

ICREA Prof.

Dir. Life Sciences Dept. BSC/CNS

Dir. INB / ELIXIR-ES / IMPaCT-Data

**Research Institute
&
Europeana Infrastructure**

MareNostrum 4

Total peak performance 13.9 Pflops

- **Disk capacity 14 Pbytes**
- **Total storage capacity 115 Pbytes**

800 scientist and engineers

**4 Departments: Earth, Engineering,
Computer Science & Life**

The third Spanish Institution in EU funding

MareNostrum5

GPP - General Purpose

Intel Sapphire Rapids

Peak performance: 45,4 Pflops
Sustained HPL: **35,4 Pflops**

April 2023

InfiniBand NDR 200 Fat Tree

Spectrum Scale File System
248 PB HDD
2,81 PB NVMe
402 PB tape

January 2023

ACC – Accelerated

Intel Sapphire Rapids
NVIDIA Hopper

Peak performance: 260 Pflops
Sustained HPL: 163 Pflops

June 2023

NGT GPP - Next Generation

NVIDIA Grace

Peak performance: 2,82 Pflops
Sustained HPL: 2 Pflops

June 2023

Consortium



Barcelona
Supercomputing
Center
Centro Nacional de Supercomputación


NGT ACC - Next Generation

Intel Emerald Rapids
Intel **Rialto Bridge**

Peak performance: 6 Pflops
Sustained HPL: 4,24 Pflops

December 2023

Code development



Data workflows

Big data

ORCA 2	ORCA 1/12
550 MB of memory	414 Gigabytes of memory
8 CPU hours	90 000 CPU hours
10 Gigabytes of output (daily)	1 Terabyte of output (daily)

Computational Earth Sciences



Digital Twin Earth

Climate Modelling




Process understanding

Environmental Services

Visualisation

Climate impacts



User engagement

BSC – LIFE Sciences

170 scientists/engineers

6 research groups

7 Support Units

**Bio-Data
management & data
infrastructures**

*NLP: Large Language
Models & BioNLP*

*Bioinformatics
Methods &
workflows*

*Data and societal
challenges*

*Biases in Biomedicine
and AI/ML*

BIOINFO 4 WOMEN

**Human Virtual
Twin**

**Personalised
Medicine**

*Rare
Diseases*

*Cancer
Research*

*Genome
Regulation*

*Genome
Wide
studies*

*Dynamical
Models*

*Design of drugs
and vaccines*

*Language Models
and AlphaFold*

**Molecular & Cellular
Modelling and Design**

BSC – LIFE Sciences

170 scientists/engineers

6 research groups

7 Support Units

**Bio-Data
management & data
infrastructures**

*NLP: Large Language
Models & BioNLP*

*Bioinformatics
Methods &
workflows*

*Data and societal
challenges*

*Biases in Biomedicine
and AI/ML*

BIOINFO 4 WOMEN

**Human Virtual
Twin**

**Personalised
Medicine**

*Rare
Diseases*

*Cancer
Research*

*Genome
Regulation*

*Genome
Wide
studies*

*Dynamical
Models*


*Design of drugs
and vaccines*

**Molecular & Cellular
Modelling and Design**


*Language Models
and AlphaFold*

- **BioMedical Data**
 - **IMPACT-Data**
- **AI/ML in Biomedicine**
 - **bioNLP + NLP in Spanish**
- **Digital Twins (Virtual Human Twins)**
- ***Rare Diseases a Computational Approach***
- **Sex and Gender biases in biomedicine and AI**

Integration of multiple biomedical data sets



Howard H.F. Tang, et al. *European Respiratory Journal* 2020



Navarro, F.C.P., Mohsen, H., Yan, C. et al. *Genomics and data science: an application within an umbrella. Genome Biol* 20, 109 (2019)

The European Health Data Movement - for Research

European Health Data Space



This initiative is a commitment of **23 European countries** to give **cross-border access** to one million sequenced genomes by 2022



ELIXIR - Nodes of European infrastructure for biological information

Data infrastructure for Europe life-science research:


- ☰ Data
- ✓ Interoperability
- 🔧 Tools
- 💻 Compute
- 👤 Training



- ELIXIR Nodes build local bioinformatics capacity throughout Europe
- Over 180 institutes involved in ELIXIR Nodes

www.elixir-europe.org

@ELIXIREurope



IMPACT-Data



Bioinformática INB/ELIXIR-ES

- BSC
- CRG
- FPS
- CNIO
- CSIC
- IRB Barcelona
- UMA
- UPF

Informática Médica & imagen

- H120
- HCB
- IACS
- IDIAPJGol
- IIS La Fe (II)
- Navarrabiomed -
- SAS-HUVR
- ISCIII
- FISABIO
- IIS La Fe
- INIBICA

Agencias Evaluadoras

- RedETS
- CTI-SEIS –
- AQuAS
- AEMPS


Demostradores Tecnológicos

- (Empresas
- BITAC
- IBM
- IVA/OpenCGA
- llumina
- Roche Pharma
- Fujitsu

Caso de uso de B1MG: enfermedades raras

Rare Diseases activities at ELIXIR FI – B1MG PoC

- Links GA4GH Standards and RD services
 - Federated EGA, Beacon, REMS, RD-Connect GPAP
- Using PoC to investigate ELSI issues
- Uses synthetic dataset
 - Aim to dope the genetic data with clinically relevant monogenic variants and associated phenotypes
- Building links with EJP-RD and Solve-RD



- Data is provided by **research centers** and **health care institutions**.
- Access is controlled by Data Access Committees.
- Data requesters are researchers from other research or **health care institutions**.

European institutes commit to data access across borders


Research institutes from five European countries have committed to improving the way researchers discover and access sensitive human data across national borders to enable more efficient health research.



Credit: Karen Arnott/EMBL

Finland, Germany, Norway, **Spain**, Sweden

Requesters by country



Data updated on February
2nd, 2022



INVESTIGACIÓN CIENTÍFICA >

El almacén invisible que guarda datos genómicos de un millón de personas

El Archivo Europeo de Genomas y Fenomas, que dispone de 16 petabytes de datos de salud muy sensibles para investigación científica, está custodiado en el superordenador MareNostrum de Barcelona y en Cambridge

The EGA allows going from data to therapy all around the world


Published: 27 October 2010

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

Peter J. Campbell, Shinichi Yachida, Laura J. Mudie, Philip J. Stephens, Erin D. Pleasance, Lucy A. Stebbings, Laura A. Morsberger, Calli Latimer, Stuart McLaren, Meng-Lay Lin, David J. McBride, Ignacio Varela, Serena A. Nik-Zainal, Catherine Leroy, Mingming Jia, Andrew Menzies, Adam P. Butler, Jon W. Teague, Constance A. Griffin, John Burton, Harold Swerdlow, Michael A. Quail, Michael R. Stratton, Christine Iacobuzio-Donahue & P. Andrew Futreal

Nature 467, 1109–1113(2010) | Cite this article

3186 Accesses | 885 Citations | 29 Altmetric | Metrics



(1) Study deposited EGAS00000000064


- ★ The paper has over 700 citations
- ★ Datasets re-used many, many times

Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer

Amish Kapoor,^{1,2} Wentong Yao,^{3,4,5} Haojiang Ying,^{3,4,5} Sujun Hu,⁶ Alison Liewen,⁷ Qiyun Wang,⁸ Yi Zhong,⁹ Chang-Jun Wu,⁹ Anuraj Sadanandam,^{1,2} Baoli Hu,¹⁰ Qing Chang,¹¹ Gerald C. Chu,¹² Ramsey Al-Khalil,¹³ Shan Jiang,¹⁴ Honglai Xia,¹⁵ Elliot Fletcher-Sanankone,¹⁶ Carol Lim,¹⁷ Gillian I. Honnelt,¹⁸ Andrea Viale,^{1,2} Piergiorgio Pittacconi,^{1,2} Nora Sanchez,^{1,2} Huasen Wang,¹⁹ Alessia Protopopou,²⁰ Jianhua Zhang,²¹ Timothy Heffernan,²² Randy L. Johnson,²³ Lynda Chin,²⁴ Y. Alan Wang,²⁵ Giulio Dretillo,^{1,2,26} and Ronald A. DeFino^{1,2}

¹Department of Cancer Biology
²Department of Genomic Medicine
³Department of Molecular and Cellular Oncology
⁴Institute for Applied Cancer Science
⁵Department of Pathology
⁶Department of Biochemistry and Molecular Biology
⁷University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
⁸The Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 3NG, UK
⁹Swiss Institute for Experimental Cancer Research (SIREC), The Swiss Federal Institute of Technology Lausanne (EPFL), Station 18, 1015 Lausanne, Switzerland
¹⁰Department of Pathology, Bingham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
¹¹Co-first author
¹²Correspondence: hying@mdanderson.org (H.Y.), rddefino@mdanderson.org (R.A.D.)
<https://doi.org/10.1016/j.cell.2016.06.003>

(2) Molecular mechanism identified



(3) New therapeutic strategy shaped

> Cancer Lett. 2017 Aug 28;402:61–70. doi: 10.1016/j.canlet.2017.05.015. Epub 2017 May 30.


A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer

Xiao Zhao¹, Xiuchao Wang², Lijun Fang³, Chungun Lan², Xiaowei Zheng², Yongwei Wang¹, Yinlong Zhang⁴, Xuexiang Han¹, Shaoli Liu⁴, Keman Cheng¹, Ying Zhao¹, Jian Shi¹, Jiayi Guo¹, Jihui Hao², He Ren⁵, Guangjun Nie⁶

Affiliations + expand

PMID: 28576749 DOI: 10.1016/j.canlet.2017.05.015

Example of potential use: Building a Virtual Cohort in a Federated Environment



*A federated operation is executed in each of the centers / nodes on their private OMOP repositories – after consultation with the ethic committee(s). **Requires interoperable data***

1.- Compartir datos clínicos para investigar

1.- **A basic standardized model of clinical data** organized in ISO13606 archetypes agreed between HCB, H12dO and HVdR, with maximum granularity

- Patient (non-identifying demographics)
- Episodes and movements (care actions)
- Laboratory determination
- Clinical observation (signs, symptoms, states)
- Limitation of therapeutic effort
- Health problems
- Diagnoses and Procedures
- Medication prescribed, administered and accumulated

2.- ADL file and its representation in **owl** for each archetype

3.- **A standardized terminological** reference for the elements of the archetype (CIM10-MC, SNOMED-CT, LOINC)

4.- **A repository of ISO13606 extracts**

5.- **Optimized transformation tools** from raw formats to archetypal extracts (LinkEHR®-Veratech)

6.- Processes to **convert archetyped data in ISO13606 to OMOP**: Extracts 13606 API ontology instances SPARQL queries OMOP tables.

7.- **OMOP repository.** Successful proof of concept carried out with a small subset of patients. Pending to populate it definitively.

8.- **Availability of views (templates)** on databases based on the definition of archetypes to model ad hoc extractions of data from primary data sources that do not necessarily have to be medical records

Federated Secure Access and Software Execution


- Single password access to distributed data hubs
- Distributed computing in secure sites under a federated protocol
- Implementing GA4GH and ELIXIR technology
- Aligned with the EHDS and GDI developments

Demo: restricted access to allowed data sets for users with different access rights.



https://www.youtube.com/watch?v=gDN_3ktHYuE

Demo: computing (variant calling) in 4 sites with private genomic data, collect data and provide summary of detected mutations.





<https://www.youtube.com/watch?v=vzb6uUyY-AQ>


La infraestructura computacional federada

Distributed infrastructure ("IMPACT-Data cloud")

- Unified computing and data Access control/authentication
- Nodes with different attributions
 - Central Node
 - Single access point users
 - Virtual environment with private workspaces
 - Data server and tools
 - Execution Orchestrator
 - Access credentials management
 - Computational nodes
 - Analysis execution
 - Data nodes
 - Data providers (omics, phenoclinics, etc.)
- Management of sensitive data based on the federated EGA model



Transparent access to normalised and interoperable data and the appropriate compute



PERSPECTIVE

Patient Dossier: Healthcare queries over distributed resources

October 17, 2019

Miguel Vazquez^{1,2}, Alfonso Valencia^{1,3*}

PLOS COMPUTATIONAL BIOLOGY



- **BioMedical Data**
 - **IMPACT-Data**
- **AI/ML in Biomedicine**
 - **bioNLP + NLP in Spanish**
- **Digital Twins (Virtual Human Twins)**
- ***Rare Diseases a Computational Approach***
- **Sex and Gender biases in biomedicine and AI**

Predicción de estructura de proteínas. El mayor logro de la IA – y un cambio paradigmático en ciencia.



Premio Princesa de Asturias de Investigación Científica y Técnica 2022



Geoffrey Hinton, Yann LeCun, Yoshua Bengio y Demis Hassabis


Premio Fronteras del Conocimiento



Demis Hassabis, David Baker y John Jumper.

Big milestone: 1M+ researchers have now made use of #AlphaFold in their vital work, in the 18 months since we made it freely available.

From antibiotic resistance to crop sustainability, it's been amazing to see the impact of 'Science at Digital Speed': unfolded.deepmind.com/#stories



5 168K views

Accelerating our understanding of early onset Parkinson's

Zhong Yan Gan uncovers crucial insights into the molecular basis of the neurological disorder



"This could accelerate drug discovery in a way that we've never seen before"

Karen Akinsanya is searching for transformative new medicines



Making AlphaFold's predictions available to scientists around the world

Prof Dame Janet Thornton and Mihaly Varadi are helping transform biology



Luigi Vitagliano is paving the way to solving a 60-year-old genetic mystery

His team at the Institute of Biostructure and Bioimaging IBB, in Naples, Italy, are researching how the function of a family of disease-causing proteins has evolved over time



Unlocking the mystery of the demon-duck of doom

Beatrice Demarchi, Josefin Stiller and Matthew Collins solve an eggshell controversy with palaeoproteomics



Accelerating the race to treat a deadly parasitic disease

Benjamin Perry is closing in on a treatment that could help millions



Accelerating the fight against plastic pollution

John McGeehan and Rosie Graham's breakthrough with an email



Unlocking the nuclear pore complex

Pietro Fontana is part of a global effort piecing together one of biology's hardest puzzles



Matthew Higgins is unlocking a new path to stop malaria in its tracks

AI is helping Matthew Higgins and his team develop a vaccine that could dismantle the malaria parasite's ability to infect humans, potentially saving hundreds of thousands of lives every year

"We need to help people start fighting osteoporosis before it's even begun"

Melissa Formosa is unlocking new ways to predict and fight the onset of osteoporosis

Unlocking a decade of data to fight antibiotic resistance

Marcelo Sousa and Megan Mitchell solved a ten-year problem in minutes



"For me, AlphaFold is transformative"

Pedro Beltrao is unlocking the secrets of our evolutionary past



"It took me two days to do something that could have taken me years"

Vilde Leipart is helping to protect honeybees



AlphaFold has changed the field of structural bioinformatics forever, with immediate implications for biotechnology and drug development.

AlphaFold covers the protein universe >200M proteins

Article


Highly accurate protein structure prediction with AlphaFold

Nature | Vol 596 | 26 August 2021 |

Article

Highly accurate protein structure prediction for the human proteome

Nature | Vol 596 | 26 August 2021



Making AlphaFold's predictions available to scientists around the world


Prof Dame Janet Thornton and Mihaly Varadi are helping transform biology

see the impact of Science at Digital Speed : unfolded.deepmind.com/#stories

JANUARY 19, 2023

New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer

by University of Toronto



AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor†

Chemical Science

Received 14th October 2022
Accepted 5th January 2023

DOI: 10.1039/d2sc05709c

ChatGPT. GPT3 - Inteligencia Artificial - Machine Learning

ChatGPT

chatgpt puede resolver todos los problemas de la humanidad



Como modelo de lenguaje, mi capacidad es proporcionar información y sugerir soluciones basadas en el conocimiento disponible en mi base de datos. Sin embargo, hay muchos problemas complejos y multifacéticos en el mundo que necesitan soluciones que requieren habilidades y conocimientos especializados más allá de lo que una máquina como yo puede proporcionar.

Traducción automática	Asistentes de voz	Resumen automático
Sistemas de pregunta respuesta	Extracción de información	Descripción de imágenes
Generación de voz y texto	Sistemas conversacionales	Análisis de sentimientos


- **MarIA** - Corpus Biblioteca Nacional de España. 120 mM tokens. **GPT-2-large**. (192 GPUs - 16gb / GPT-2 takes 32*4 GPUs for a week)
- **AINA** - Corpus catalán, 1.7 mM tokens. 1st **RoBERTa**



politiquesdigitals.gencat.cat

Europe Needs Language Specific Model

Technological Support for the European Official Languages




Barcelona Supercomputing Center

EU official languages

- Bulgarian
- Croatian
- Czech
- Danish
- Dutch
- English
- Estonian
- Finnish
- French
- German
- Greek
- Hungarian
- Irish
- Italian
- Latvian
- Lithuanian
- Maltese
- Polish
- Portuguese
- Romanian
- Slovak
- Slovenian
- Spanish
- Swedish




La adaptación de los modelos a lenguajes específicos con los expertos de dominio



Iterative correction of automatic annotations until system is perfected powered by HPC resources

use human knowledge automatically to learn



Ejemplo de anotación de un curso clínico del Hospital Clinic

- HIPERTENSIÓN ARTERIAL en tratamiento hace >10 años.

*Ecocardiografía 12/2019: FE 58%, valvas normales, ligera hipertrofia septal, no dilatación de cavidades, patrones de disfunción diastólica tipo I, no trastornos de la contractilidad, FSG conservada, no IT ni signos de HTP.

*ECG: RS a 98 lpm, eje a 0o, PR <0.20seg, QRS estrecho, buena progresión de onda R en precordiales, no alteraciones de la repolarización ni signos de isquemia aguda.

- LITIASIS RENALES POR ÁCIDO ÚRICO en tratamiento con alopurinol sin nuevos episodios desde hace 15 años (no tenemos informes).

MEDICACIÓN HABITUAL 8/11/2020

- Metformina 425 mg/8h presenta forma de banda lo que indicaría cierto grado de neumonía organizativa.

ENTIDADES CLÍNICAS

- **SINT:** Síntoma
- **ENF:** Enfermedad
- **PROC:** Procedimiento
- **FARM:** Fármaco
- **SPECIES:** Organismo Vivo

ENTIDADES TEMPORALIDAD

- **DATE:** Fechas
- **TIME:** Horas
- **DURATION:** Duraciones
- **SET:** Frecuencia

ENTIDADES LINGÜÍSTICAS

- **NEG:** Marcador Negación
- **NSCO:** Alcance Negación
- **UNC:** Marcador Especulación
- **USCO:** Alcance Especulación

Casos Reales Hospital Clinic : anotación curso clínico



Plan TL
Plan de impulso de las
Tecnologías del Lenguaje



SECRETARÍA DE ESTADO
DE DIGITALIZACIÓN
E INTELIGENCIA
ARTIFICIAL

CLÍNIC
BARCELONA
Hospital Universitari

ORG_VIVO **PACIENTE-PROFESION** **ENFERMEDAD** **ENFERMEDAD** **FARMACO** **NEG**
Varón de 50 años, transportista de alimentos empaquetados. Exfumador, hipertenso en tratamiento con Enalapril sin
NSCO **ENFERMEDAD** **SINTOMA** **SINTOMA** **SINTOMA** **SINTOMA** **SINTOMA**
otros antecedentes de interés o hábitos tóxicos. Ingresa por cuadro de 4 días de evolución de **astenia**, **hiporexia**, **dispepsia**, **cefalea**, **mialgias**,
SINTOMA **SINTOMA** **SINTOMA** **NEG** **NSCO** **NEG** **NSCO** **ORG_VIVO** **NEG**
prurito, **coluria** y **acolia**. Niega **fiebre**. Niega consumo de drogas, productos de parafarmacia, setas silvestres o nuevos fármacos. Niega

NSCO **PACIENTE-PROFESION**
ORG_VIVO **NEG** **ORG_VIVO** **ORG_VIVO** **ORG_VIVO**
Presentamos el caso de una **mujer** de 38 años, sin antecedentes personales ni familiares de interés y de profesión **pescadera** desde
SINTOMA **ENFERMEDAD**
los 17 años. Acude a urgencias por un cuadro de **prurito generalizado** y **lesiones habonosas confluentes por todo el cuerpo**, precisando dosis altas
PROCEDIMIENTO **PROCEDIMIENTO**
de **corticoides** y **antihistamínicos** para su cese. Un mes más tarde vuelve a reproducirse idéntica sintomatología, acompañada además en esta
SINTOMA **SINTOMA** **FARMACO** **PROCEDIMIENTO** **ORG_VIVO**
ocasión de **poliartralgias** y **rigidez**, sobre todo en rodillas y tobillos, con buena respuesta a **indometacina**. En la **anamnesis**, la **paciente** refería

ORG_VIVO **PACIENTE-PROFESION** **ORG_VIVO** **NEG** **NSCO**
Varón de 53 años, **empresario**, sin **alergias medicamentosas conocidas ni hábitos tóxicos**. Acudía a nuestra consulta acompañado por
ORG_VIVO **ENFERMEDAD**
su **mujer**. Estaba diagnosticado de una **miastenia gravis** con afectación ocular y bulbar de 20 años de evolución, timentomizado y en tratamiento
FARMACO **FARMACO** **NEG** **NSCO**
con **azatioprina** 100 mg al día y **piridostigmina** 180 mg al día. No **seguía controles rutinarios** por parte de Neurología.

23 clases de conceptos

Personas



- PACIENTE-PROFESION
- FAMILIAR-PROFESION
- SANITARIO-PROFESION
- PACIENTE-SITUACION_LABORAL
- FAMILIAR-SITUACION_LABORAL



Conceptos clínicos

- SINTOMA** *symptoms*
- ENFERMEDAD** *diseases*
- FARMACO** *drugs*
- PROCEDIMIENTO** *procedures*
- ORG_VIVO** *living beings*

Modificadores

- NEG** **NSCO** *negation trigger and scope*
- UNC** **USCO** *uncertainty trigger and scope*

A. Estructuración de datos

```

INPUTTEXT: [
  {
    "A-ID": "T1",
    "B-TYPE": "PROCEDIMIENTO",
    "C-START": "576",
    "D-END": "594",
    "E-text": "exploración física",
    "F-snomed": "425044008+129432007+5880005"

    "A-ID": "T2",
    "B-TYPE": "PROCEDIMIENTO",
    "C-START": "643",
    "D-END": "668",
    "E-text": "auscultación respiratoria",
    "F-snomed": "NIL"
  }
]
    
```

JSON




ID	TYPE	START	END	TEXT	SNOMED
T1	PROCEDIMIENTO	576	594	exploración física	425044008+129432007+5880005
T2	PROCEDIMIENTO	643	668	auscultación respiratoria	NIL
T3	PROCEDIMIENTO	843	861	electrocardiograma	29303009
T4	PROCEDIMIENTO	947	967	radiografía de tórax	55587003
T5	PROCEDIMIENTO	1099	1118	frotis nasofaríngeo	NIL
T6	PROCEDIMIENTO	1541	1556	ecocardiografía	40701008
T7	PROCEDIMIENTO	2035	2050	coronariografía	NIL

CSV

ID	TYPE	START	END	TEXT	SNOMED
T1	PROCEDIMIENTO	576	594	exploración física	425044008+129432007+5880005
T2	PROCEDIMIENTO	643	668	auscultación respiratoria	NIL
T3	PROCEDIMIENTO	843	861	electrocardiograma	29303009
T4	PROCEDIMIENTO	947	967	radiografía de tórax	55587003
T5	PROCEDIMIENTO	1099	1118	frotis nasofaríngeo	NIL
T6	PROCEDIMIENTO	1541	1556	ecocardiografía	40701008
T7	PROCEDIMIENTO	2035	2050	coronariografía	NIL
T8	PROCEDIMIENTO	2150	2176	de un catéter de Swan-Ganz	NIL
T9	PROCEDIMIENTO	2284	2310	reanimación cardiopulmonar	89666000
T10	PROCEDIMIENTO	2312	2340	pericardiocentesis emergente	NIL

TSV

B. Timeline/panel de control



C. Red de conocimiento, análisis de datos, grafo de relaciones clínicas


Plot network Refresh session

Network visualization panel

Filter by co-occurrence count: 1 to 100 (set to 21)

Select labels:

- PROCEDIMIENTO
- SINTOMA
- FARMACO
- EDAD-SUJETO-ASISTENCIA
- ENFERMEDAD
- ENTIDAD-OBSERVABLE
- FECHAS
- PROTEINAS
- SPECIES
- TERRITORIO
- PAIS
- SEXO-SUJETO-ASISTENCIA
- ID-SUJETO-ASISTENCIA
- CALLE
- HOSPITAL



Co-occurrence Node ranking Communities

word1	word2	count word1	count word 2	count of co-occurrences	PMI
lopinavir	ritonavir	38	40	38	2.32
dimero D (entidad-observable)	dimero D (farmaco)	38	29	27	2.29
frecuencia respiratoria	presión arterial	50	52	33	1.34
exploración física	presión arterial	43	52	25	1.16
azitromicina	hidroxicloroquina (farmaco)	47	69	35	1.11
frecuencia respiratoria	temperatura	50	74	36	0.96

- **BioMedical Data**
 - **IMPACT-Data**
- **AI/ML in Biomedicine**
 - **bioNLP + NLP in Spanish**
- **Digital Twins (Virtual Human Twins)**
- *Rare Diseases a Computational Approach*
- **Sex and Gender biases in biomedicine and AI**

Digital twins

HORIZON
The EU Research &
Innovation Magazine


INDUSTRY SCIENCE IN SOCIETY ICT

How digital 'twins' are guiding the future of maintenance and manufacturing

15 November 2019




GE Healthcare is building digital twins of hospitals, mining data to improve performance at the individual asset and entire network level



Gemelos Digitales para la Medicina del Futuro

Quando será posible?
Para que aplicaciones?



Simulations & FDA

Model-Informed Drug Development Paired Meeting Program

 fda.gov
https://www.fda.gov › drugs › mo... · Traducir esta página

Model-Informed Drug Development Paired Meeting Program

31 oct 2022 — Provide an opportunity for **drug** developers and **FDA** to discuss the application of MIDD approaches to the development and regulatory evaluation of ...

GATC Health Welcomes the FDA Modernization Act 2.0, Allowing New Drug Candidates to Bypass Animal Testing Using Computer Modeling

NEWS PROVIDED BY
GATC Health Corp →
Jan 25, 2023, 09:55 ET

IC sees expanding role for computational modeling and simulation in med tech

... ..McCarthy Jan. 31, 2023

Computational modeling and simulation (CM&S) isn't the new flavor of the month in the medical device industry, but it hasn't exactly achieved the status of a buzzword, either. However, the Medical Device Innovation Consortium (MDIC) has published a report which makes clear that these software tools are continuing to open new frontiers in device development, a trend that seems certain to continue to expand in the decades ahead as to-market costs continue to grow.

Congress Approves Landmark Measure to Reduce Animal Testing

FDA Modernization Act promises to spare animals, bring safer and better treatments to patients, and drive down drug prices

December 23, 2022 18:48 ET | Source: [Animal Wellness Action](#)

What is the FDA Modernization Act 2.0, and what does it mean?

The U.S. Food and Drug Administration (FDA) are the federal agency tasked with approving new drugs for use within the United States (U.S.). On the 29th of September 2022 the U.S. Senate unanimously passed Bill S. 5002, the "FDA Modernization Act 2.0." On Dec 23rd 2022, the U.S. House gave its **final approval**. This has subsequently been signed into law by President Biden. In this landmark measure, the Federal Food, Drug, and Cosmetic Act dating back to 1938 will now be updated to reflect the advances of modern science. But why is this such a big deal?

February 14, 2023

Medical Device Computational Modeling and Simulation Reports Highlights Best Uses and Barriers to Adoption

By MedTech Intelligence Staff

 No Comments



"This report validates the broad applicability—and true value—of computational modeling and simulation as a critical engineering discipline. Tangible cost, quality and performance improvements are being realized by the early adopters."

Towards a Human Digital Twin


Simulations from molecules, to cells, to organs ...



By Victor Guallar ICREA & BSC







Current time: 0 days, 0 hours, and 0.00 minutes
18317 agents



By Mariano Vazquez, CASE - BSC

*By Arnau Montagud
MABOSS Cell Modelling Framework
Col Physicell by P Macklin, Indiana U*

Introducing simulations in the genomic world







HUMAN
CELL
ATLAS



“Reemplazar la generación actual de métodos bioinformáticos con modelos celulares, proporcionando descripciones mecanicistas e hipótesis comprobables, en lugar de las actuales aproximaciones estadísticas y descripciones intuitivas”









From Bulk to Single-cell sequencing



Jovic D et al. Single-cell RNA sequencing technologies and applications: A brief overview. *Clin Transl Med.* 2022 Mar;12(3):e694

Agent-based with probabilistic logical model allows for finding optimal drug regimes



Proliferation Apoptosis Necrosis



Simulaciones de tumores & microambiente – tumores simulados NO SON como tumores reales ...pero pueden ser útiles

Cell Cycle Phase

- Premitotic
- Postmitotic
- Kl67 negative
- Apoptotic
- Necrotic
- Necrotic (swelling)
- Necrotic (lysis)



La historia elabora un concepto encontrado en *Silvia y Bruno* de *Lewis Carroll*: un mapa ficticio que tenía una escala de "una milla por milla". Uno de los personajes en la historia de Carroll hace notar varias de las dificultades prácticas con el mapa y asegura que "ahora usamos el país mismo como su propio mapa, y [le] aseguro que funciona casi igual de bien".

La historia de Borges, citada ficcionalmente como de "Suárez Miranda, Viajes de varones prudentes, Libro IV, cap. XLV, Lérida, 1658", imagina un imperio en el que la ciencia de la cartografía se vuelve tan exacta que sólo un mapa a escala del imperio mismo será suficiente: "las Generaciones Siguientes entendieron que ese dilatado Mapa era inútil y no sin impiedad lo entregaron a las inclemencias del Sol y los Inviernos. En los desiertos del Oeste perduran despedazadas Ruinas del Mapa, habitadas por Animales y por Mendigos".^[1]

Inteligencia Artificial y Simulaciones Dinámicas

IA>SM Exploración Espacio de parámetros

SM>IA Generar datos para entrenar modelos de ML

IA>SM Predecir el curso de las simulaciones

SM>IA Interpretar en términos mecánicos los resultados de AI

IA>SM Analizar los grandes conjuntos de resultados de las simulaciones

SM>IA Inteligencia artificial informada con leyes físicas

<> Modelos mixtos AI/Simulación


- **BioMedical Data**
 - **IMPACT-Data**
- **AI/ML in Biomedicine**
 - **bioNLP + NLP in Spanish**
- **Digital Twins (Virtual Human Twins)**
- ***Rare Diseases a Computational Approach***
- **Sex and Gender biases in biomedicine and AI**

Congenital myasthenic syndrome project




Severe

Non-severe




A Personalized medicine approach




Cohort Characteristics
 20 patients:
 8 severe
 12 non-severe


Same causal homozygous mutation in the CHRNE gene (CHRNE c.1327delG)



Severity in Congenital Myasthenic Syndromes




Algorithm clustering in multilayers networks




Severe and non-severe communities have different actors and functions

Severe



Non-severe



Compound heterozygous variants



Copy number variants



Known CMS gene




Activity localization	Class	CMS causal gene	Phenotype group		Function	Synaptic localization (Manual curation)	Localization (UniProt)
			Not-severe	Severe			
ECM (ECM)	Proteoglycans	AGRN	-	AGRN	Cell hydration and growth factor trapping	Pre- and post-synaptic (PMID:29462312)	Synaptic basal lamina / ECM
		-	-	HSPG2		Basement membrane (PMID:30453502)	Basement membrane / ECM
		-	-	VCAN		ECM (PMID: 29211034)	ECM
		-	-	COL15A1		Basement membrane (PMID:26937007)	ECM
	Collagens	COL13A1	-	-	Structural support	Basement membrane, post-synaptic (PMID:30768864)	Post-synaptic cell membrane
		-	COL6A5	-		Basement membrane (PMID:23869615)	Extracellular matrix
	Laminins	LAMA5	-	-	Web-like structures	Pre-synaptic (PMID:28544784)	Basement membrane / ECM
		LAMB2	-	-		Basement membrane (PMID:27614294)	Basement membrane / ECM / Synaptic cleft
		-	LAMB4	-		Myenteric plexus basement membrane (PMID:28595269)	Basement membrane / ECM
		-	-	LAMA2		Pre-synaptic (PMID: 9396756)	Basement membrane / ECM
		-	-	USH2A		Neuronal projection of stereocilia (PMID:19023448)	Stereocilium membrane / Secreted (Extracellular region)
		-	-	-		Glomerular Extracellular matrix (PMID:29486390)	Basement membrane / ECM
	Fibulins	-	HMCN1	-	Scaffolding	Basement membrane (PMID:29466693)	ECM / Perisynaptic ECM (Ensembl)
	Tenascins	-	-	THN	Anti-adhesion	Basement membrane (PMID:23768946)	ECM
	-	-	LOXL3	Collagen assembly		Basement membrane (PMID:26954549)	Secreted (extracellular region)
	Enzymes	-	ADAMTS9	-	Proteoglycan cleavage	Secreted to ECM (PMID:30626608)	ECM
			ADAM28	-		ECM (PMID:24613731)	Cell membrane / Secreted (extracellular region)
			-	-		Pre- and post-synaptic (PMID:7526287)	Secreted (extracellular region)
Neuropeptides	-	-	CHGB	Regulatory peptides precursor	ECM (PMID:27143355)	Secreted (extracellular region)	
Others	-	ITIH5	-	Hyaluronic acid binding	-	-	
Cell surface	Receptors	-	MSR1	Proteoglycan and collagen binding	Macrophage surface Scavenger Receptor (PMID:12488451)	Plasma membrane	
		-	MCAM		Plasma membrane (PMID:28923978)	Plasma membrane	
		-	LRP4	-	Laminin binding	Post-synaptic (PMID:25319686)	Post-synaptic cell membrane
Cytoplasm	Cytoskeleton	PLEC	-	Structural support	Post-synaptic (PMID:20624679)	Post-synaptic cytoskeleton	




Lochmüller's lab, Ottawa




Decreased chorion movement
(1 day post fertilisation)



Decreased muscle fibre thickness
(5 days fish)



Decreased number of AChR clusters
(5 days fish)



Data Aggregation and Interpretation




Individualized
PaediatricCure

Cloud-based virtual-patient models
for precision paediatric oncology

5 Paediatric cancers

- **Medulloblastoma (MB)**
- Ewing Sarcoma (ES)
- Neuroblastoma (NB)
- Hepatoblastoma (HB)
- Acute Lymphoblastic Leukemia (ALL)




Northcott et al. *Nature*. 2017
Taylor et al. *Acta Neuropathol.* 2012

Patient stratification in medulloblastoma

(~14,000 altered genes per patient)

(~1,800 altered genes per patient)




95% accuracy

87% dimensionality reduction

Forget et al. *Cancer Cell*. 2018
Nuñez et al. *Cell iScience*. 2021

A multilayer network to combine genomics and real world data in medulloblastoma

Methylation: 54 nodes
 Phospho: 42 nodes
 Protein: 46 nodes
 RNAseq: 60 nodes
 Textmining: 100 nodes



Interpretability: Multilayer community labelling

ClusterID:1 ||

Syndrome_Sotos

GLI1

PROM1

MTOR

PTCH1

MB54

MB15

MB13

MB07

MB17

MB09

MB43

MB24

MB53

VEGFA

MB47

AKT1

MB02

TNFSF10

OTX2

MB01

ClusterID:2 ||

EN1

EN2

CTNNB1

MB30

MB21

MB48

MB39

MB20

MB25

MB06

MB04

MYCN

MDM2

ClusterID:6 ||

MESH:C059514

MESH:C047246

Thiotepa

Carboplatin

Cisplatin

O(6)-benzylguanine

Etoposide

Cyclophosphamide

Methotrexate

Carmustine

Lomustine

Vincristine

ClusterID:3 ||

CDKN2A

Basal_Cell_Nevus_Syndrome

Adenomatous_Polyposis_Coli

Carcinoma_Basal_Cell_Pigmented

GFAP

SUFU

MB34

MB33

MB31

MGMT

MYC

MB08

MB40

MB51

MB14

MB03

TP53

CASP8

ClusterID:4 ||

Rhabdoid_Tumor

Rhabdomyosarcoma

Craniopharyngioma

Lymphoblastic_Leukemia_Acute_Childhood

Neuroectodermal_Tumors

Glioma

Neuroblastoma

Oligodendroglioma

Neuroectodermal_Tumor_Primitive

Meningioma

Ependymoma

Pinealoma

Embryonal_Neoplasm

Central_Nervous_System_Neoplasms

Malignant_Neoplasms

Glioblastoma

Astrocytoma

Brain_Neoplasms

ClusterID:5 ||

Nausea

Hearing_Impairment

Thrombocytopenia

Paracousis

Cognition_Disorders

Mutism

Vomiting

Ataxia

Headache

Neurologic_Manifestations

Jacksonian_Seizure

Neutropenia

Hypothyroidism

Neoplasm_Metastasis

Leukemia

Bone_Marrow_Diseases

Communicating_Hydrocephalus

Cerebellar_Diseases

Infratentorial_Neoplasms

Central_Nervous_System_Diseases

GH1

Species_9606

ClusterID:7 ||

Myc

SMO

Trp53-ps

Smo

Ptch1

Shh

CellLine_CVCL:1167

Toxicity_Drug

Species_1383439

Death

Cerebellar_Neoplasms

Species_10116

Species_10090

CSF2

Medulloblastoma

NGFR

BCL2

PPM1D

ENO2

MB22

MB16

MB10

MB55

MB49

MB46

ERBB2

NTRK3

MB05

MB52

MB50

STAT3

MB19

SHH

IGFBP2

- **BioMedical Data**
 - **IMPACT-Data**
- **AI/ML in Biomedicine**
 - **bioNLP + NLP in Spanish**
- **Digital Twins (Virtual Human Twins)**
- ***Rare Diseases a Computational Approach***
- **Sex and Gender biases in biomedicine and AI**

Sex & Gender Biases in Biomedicine, AI and NLP

How AI systems amplify bias

Image recognition systems that use biased machine learning data sets will inadvertently magnify that bias. Researchers are examining ways to reduce the effects.

ROLE	VALUE
AGENT	WOMAN
FOOD	PASTA
HEAT	STOVE
TOOL	SPATULA
PLACE	KITCHEN


ROLE	VALUE
AGENT	WOMAN
FOOD	FRUIT
HEAT	—
TOOL	KNIFE
PLACE	KITCHEN

ROLE	VALUE
AGENT	WOMAN
FOOD	MEAT
HEAT	GRILL
TOOL	TONGS
PLACE	OUTSIDE

ROLE	VALUE
AGENT	WOMAN
FOOD	VEGETABLES
HEAT	STOVE
TOOL	TONGS
PLACE	KITCHEN

ROLE	VALUE
AGENT	MAN
FOOD	—
HEAT	STOVE
TOOL	SPATULA
PLACE	KITCHEN

In this example of gender bias, adapted from a report published by researchers from the University of Virginia and the University of Washington, a visual semantic role labeling system has learned to identify a person cooking as female, even when the image is male.



SEX AND GENDER BIAS IN TECHNOLOGY AND ARTIFICIAL INTELLIGENCE APPLIED TO BIOMEDICINE AND HEALTHCARE

Edited by DAVIDE CIRILLO, SILVINA CATUARA-SOLARZ, EMRE GUNEY

Women's Brain Project

npj | Digital Medicine

www.nature.com/npjdigitalmed

REVIEW ARTICLE OPEN

Check for updates

Sex and gender differences and biases in artificial intelligence for biomedicine and healthcare

Davide Cirillo^{1,10,11}, Silvina Catuara-Solarz^{2,3,10}, Czuze Morey⁴, Emre Guney⁵, Laia Subirats^{6,7}, Simona Mellino⁸, Annalisa Gigante⁹, Alfonso Valencia¹⁰, Maria José Rementería¹, Antonella Santuocione Chadha⁸ and Nikolaos Mavridis¹⁰

Davide Cirillo et al. BSC

.. Part of the research line of bioinfo4women

CON SUPERCOMPUTACIÓN

Identifican qué genes hacen a cada persona única y cómo esa diferencia cambia con la edad

• Las principales diferencias entre hombres y mujeres residen en los genes expresados en la tiroides y el tejido mamario



Los humanos compartimos el 99,9% de nuestro genoma (Getty)

CRISTINA SÁEZ
BARCELONA




Cell Genomics

CellPress
OPEN ACCESS

Article The landscape of expression and alternative splicing variation across human traits

Raquel García-Pérez,¹ Jose Miguel Ramirez,¹ Aida Ripoll-Ciadellas,¹ Ruben Chazarra-Gil,¹ Winona Oliveros,¹ Oleksandra Soldatkina,¹ Mattia Bosio,¹ Paul Joris Rognon,^{1,2,3} Salvador Capella-Gutierrez,¹ Miquel Calvo,⁴ Ferran Reverter,⁴ Roderic Guigó,⁵ François Aguet,^{6,10} Pedro G. Ferreira,^{7,8,9} Kristin G. Ardlie,⁶ and Marta Melé^{1,11,*}





**Barcelona
Supercomputing
Center**
Centro Nacional de Supercomputación

We look forward to welcoming you at BSC!

[@Alfons valencia](#)